lumretuzumab (RG7116) / Roche - LARVOL DELTA

The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study. (PubMed, Curr Med Chem) - "Monoclonal antibodies such as lumretuzumab, seribantumab, and patritumab have shown potential in targeting HER3 to overcome resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Additionally, antibody-drug conjugates (ADCs) like HER3-DXd (patritumab deruxtecan) are new drug candidates that have demonstrated selective delivery of cytotoxic chemicals to NSCLC cells by exploiting HER3's widespread expression, minimizing cytotoxicity. This review aims to evaluate the efficacy of current HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating evidence from clinical trials."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ERBB3 • HER-2

RG7116, a novel humanized anti-HER3 antibody with superior preclinical in vitro and in vivo efficacy in combination with, everolimus and other anti-cancer agents (AACR 2014) - Presentation time: Monday, Apr 07, 2014, 1:00 PM - 5:00 PM; Abstract #2668; "The combination of RG7116 with downstream signaling inhibitors like: everolimus (mTOR) and other anti-cancer agents leads to increased efficacy."

Preclinical • Oncology

A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology (clinicaltrials.gov) - P1; N=53; Suspended; Sponsor: Hoffmann-La Roche; Trial primary completion date: Aug 2018 ➔ Dec 2015

Trial primary completion date • Biosimilar • Non Small Cell Lung Cancer • Oncology

A study of RO5479599 alone or in combination with cetuximab or erlotinib in patients with metastatic and/or locally advanced malignant HER3-positive solid tumors (clinicaltrials.gov) - P1, N=105; Sponsor: Hoffmann-La Roche; Recruiting; Trial completion date: Oct 2014 -> Jun 2015. 

Trial completion date • Oncology